Phase III Data And GMP Nod Bring Prestige’s Trastuzumab Closer To Launch

Latest Developments Bode Well For Tuznue Biosimilar Rival To Herceptin

 
• By Dave Wallace

Prestige BioPharma says its proposed Tuznue trastuzumab rival to Herceptin is moving closer to launch in global markets, after reporting positive Phase III data for the biosimilar as well as a European GMP certification for its manufacturing facility in Korea.

Double Six Red Dice Good Luck
Two positive developments will allow Prestige to move forward • Source: Stocksolutions / Alamy Stock Photo

More from Biosimilars

More from Products